PT - JOURNAL ARTICLE AU - Kawasuji, Hitoshi AU - Tsuji, Yasuhiro AU - Miyaki, Keiko AU - Aoyama, Takahiko AU - Kurosaki, Fumihiro AU - Ezaki, Masayoshi AU - Koshiyama, Yuki AU - Takegoshi, Yusuke AU - Kaneda, Makito AU - Murai, Yushi AU - Kimoto, Kou AU - Nagaoka, Kentaro AU - Yamamoto, Yoshihiro TI - High feasibility of salivary therapeutic drug monitoring in linezolid, but less in tedizolid: A single-dose study in healthy subjects AID - 10.1101/2024.06.30.24309749 DP - 2024 Jan 01 TA - medRxiv PG - 2024.06.30.24309749 4099 - http://medrxiv.org/content/early/2024/07/01/2024.06.30.24309749.short 4100 - http://medrxiv.org/content/early/2024/07/01/2024.06.30.24309749.full AB - Background Salivary therapeutic drug monitoring (TDM) offers the potential to reduce the risks, burden, time, and costs of blood-based TDM, but its feasibility in oxazolidinone antibiotics and the influence of food intake remain unknown.Methods A total of 12 healthy volunteers participated in this study. Linezolid and tedizolid were intravenously administered to 6 participants each. Saliva samples were taken at 15 time points and peripheral venous blood samples were also taken at 12 time points simultaneously with saliva. Total and unbound serum and saliva concentrations of linezolid and tedizolid were measured using high-performance liquid chromatography.Results Individual concentration–time curves in saliva versus serum (total and unbound) were similar in linezolid, but different in tedizolid. Saliva concentrations were significantly correlated with total and unbound serum concentrations in both agents. However, concentrations in each case and area under the concentration–time curve from 0 to 10 h (AUC0–10) in saliva were correlated with those in total or unbound serum for linezolid, but not for tedizolid. The mean saliva-to-serum (total and unbound) concentration and AUC0–10 ratios were 0.90 and 0.90 in total and 1.09 and 0.99 in unbound. Food intake did not influence these correlations in linezolid.Conclusions The analysis of linezolid in saliva is applicable for TDM as a promising alternative to conventional serum sampling without correlation factors, but application of tedizolid is less feasible. Easy sampling using a noninvasive technique may facilitate TDM even in underdeveloped countries with limited resources and specific patient categories.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis study was supported by research grants from the Japanese Society of Chemotherapy Foundation (the 8th Uehara Infectious Disease and Chemotherapy Research Award to H.K.) and the Japan Society for the Promotion of Science KAKENHI program (grant number JP22K08597 to Y.Y.). The funding bodies played no role in the study design, collection, analysis, or interpretation of data, and no role in writing the manuscript.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This study was registered at UMIN (UMIN000046556) and approved by the ethical review board of the University of Toyama (approval nos. R2012133 and R2020147) and the Nihon University (approval nos. 20-005 and 23A-005). Written informed consent was obtained from all participants.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.Yes